Given the role of LSD1 as an epigenetic regulator and its effect on ASXL1 clones, it is reasonable to further study whether the treatment effect is associated with other epigenetic regulator mutations observed in a subset of myelofibrosis in clinical settings. The gene discussed is ASXL1; the disease is myelofibrosis.